NCT03461861 · Phase 2 · COMPLETED
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
This trial is testing AGB101, a low-dose extended-release form of levetiracetam (an existing seizure medication), to see whether it can calm overactive hippocampal activity in healthy older adults. The hippocampus is the brain's memory hub, and abnormal hyperactivity there is thought to be an early sign of Alzheimer's risk. Brain scans measure whether the drug changes that activity. This is a Phase 2 trial — testing whether it works and is safe, not yet proven or approved.
You may qualify if
- Fluent in English
- At least eight (8) years of education
- Geriatric Depression Scale (GDS) (62) score \< 6
- Hachinski Ischemic Score ≤ 4
- Normal general cognitive function as well as 1) normal memory function, documented by MOCA score of 23 or greater, and a RBANS Delayed Memory Index score of 85 or greater.
You're excluded if
- Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of significant head trauma or known structural brain abnormalities
- Major psychiatric disease or chronic unstable medical conditions
- History of drug abuse
- History of alcohol abuse (4 or greater drinks per day on average)
- Unable to complete MRI scans (no Pacemaker/Defibrillator)
- Known clinically significant abnormalities in B12 or thyroid function tests
- End Stage Renal Disease (ESRD)
- Hemodialysis (HD)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2023-07-03